The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Research Funding - Boehringer Ingelheim
Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi).
 
Elizabeth Dudnik
No Relationships to Disclose
 
Elias Bshara
No Relationships to Disclose
 
Ahuva Grubstein
No Relationships to Disclose
 
Ludmila Fridel
No Relationships to Disclose
 
Tzippy Shochat
No Relationships to Disclose
 
Laila C Roisman
Stock and Other Ownership Interests - Teva
Honoraria - Pfizer; Roche
Patents, Royalties, Other Intellectual Property - Interferon patents, approved
Travel, Accommodations, Expenses - Roche
 
Maya Ilouze
No Relationships to Disclose
 
Anna B Rozenblum
No Relationships to Disclose
 
Smadar Geva
No Relationships to Disclose
 
Alona Zer
Consulting or Advisory Role - Lilly; Novartis
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - AstraZeneca; Lilly; MSD; Roche
 
Ofer Rotem
No Relationships to Disclose
 
Aaron Allen
No Relationships to Disclose
 
Nir Peled
Consulting or Advisory Role - Advisor & Honorarium for AZ, BI, BMS, Lilly , MSD, Novartis, pfizer, Roche
Speakers' Bureau - Advisor & Honorarium for AZ, BI, BMS, Lilly , MSD, Novartis, pfizer, Roche